Co-repression of <i>Yap1</i> and <i>Sox9</i> Abrogates Established Cholangiocarcinoma by Eliminating Transcriptional Compensation
Co-targeting SOX9 and YAP1 offers a promising and safe broad-spectrum preventive/therapeutic approach for iCCA, potentially overcoming resistance to YAP1 inhibition. The adaptive resistance mechanism identified may extend to other malignancies, providing insights for addressing the advanced resistant to YAP1-TEAD-directed therapies.
Authors
- Shikai Hu
- Yu‐Chiao Chiu (ORCID: https://orcid.org/0000-0003-1647-8634)
- Yoojeong Park (ORCID: https://orcid.org/0009-0005-1828-7147)
- Li‐Ju Wang (ORCID: https://orcid.org/0000-0003-2745-2819)
- Jiajun Liu (ORCID: https://orcid.org/0000-0001-5068-7013)
- Laura Molina
- Silvia Liu
- Jeseph Kwon
- Sungjin Ko
- Aatur Singhi
- Minwook Kim
Institutions
- University of Pittsburgh (US)
- UPMC Hillman Cancer Center (US)
- University of Pittsburgh Medical Center (US)
- Tsinghua University (CN)
Publication Details
- Journal
- bioRxiv (Cold Spring Harbor Laboratory)
- Published
- 2026-02-02
- DOI
- https://doi.org/10.64898/2026.01.30.702953
- Primary Topic
- Hippo pathway signaling and YAP/TAZ
- Type
- article
- Field-Weighted Citation Impact
- 0.00